Nasal Spray
FDA approves a second OTC naloxone nasal spray
July 31, 2023Medical Communications FDA, Nasal Spray, OTC, OTC Products, naloxone, opioids
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg naloxone hydrochloride nasal spray for …
FDA approves prescription nasal spray for opioid overdose treatment
May 23, 2023Medical Communications FDA, Nasal Spray, Opvee, Poisoning and drug dependency, opioids, overdose
The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the first nalmefene hydrochloride nasal spray …
FDA accepts sNDA for Optinose’s XHANCE
May 5, 2023Medical Communications Ear Nose & throat, FDA, Nasal Spray, optinose, sNDA
Optinose has announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for …
Ena Respiratory’s nasal spray reduces COVID-19 replication by 96%
December 18, 2020Medical Communications COVID-19, Nasal Spray
Australian biotech Ena Respiratory has revealed that its self-administered nasal spray INNA-051, when taken once or twice weekly, reduced viral …
Drug-free nasal spray could prevent COVID-19 infection, promising data show
December 3, 2020Research and Development COVID-19, Nasal Spray, auris medical
Auris Medical has revealed promising new in vitro data for AM-301, its drug-free nasal spray, showing that the product could …
Novel prophylactic nasal spray reduced COVID-19 replication by 96% in animal studies
September 28, 2020Research and Development, Sales and Marketing COVID-19, Ena Respiratory, Nasal Spray
Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 …
European Commission authorises Janssen’s anti-depressant Spravato
December 23, 2019Sales and Marketing Janssen, MDD, Nasal Spray, TRD, depression, mental health
The European Commission has approved Janssen’s nasal spray Spravato (esketamine), which is used to treat major depressive disorder (MDD) that …
